APA (7th ed.) Citation

C, A., V, S., J, G., J, P., I, Á., DH, R., . . . M, C. (2026). Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years. The Journal of allergy and clinical immunology. https://doi.org/10.1016/j.jaci.2026.04.001

Chicago Style (17th ed.) Citation

C, Akin, et al. "Avapritinib Achieves Long-term Disease Control with Favorable Safety in Patients with Indolent Systemic Mastocytosis over 3 Years." The Journal of Allergy and Clinical Immunology 2026. https://doi.org/10.1016/j.jaci.2026.04.001.

MLA (9th ed.) Citation

C, Akin, et al. "Avapritinib Achieves Long-term Disease Control with Favorable Safety in Patients with Indolent Systemic Mastocytosis over 3 Years." The Journal of Allergy and Clinical Immunology, 2026, https://doi.org/10.1016/j.jaci.2026.04.001.